DEA

This article was originally published on MG Magazine and appears here with permission. In 1988, a federal judge brashly ruled against the Reagan administration’s drug policy and declared cannabis fit for medical use. The controversial decision nearly reclassified marijuana under the...

The Food and Drug Administration (FDA) issued an alert on the dangers of self-treating psychiatric disorders with unapproved compounded versions of ketamine and ketamine-based drugs whether modified or tailored for specific patient needs. In view of the anesthetic’s rising...

The Ninth Circuit Court of Appeals ordered the DEA on Monday to respond within 30 days to the suit arguing the agency has been “dragging their heels” for the approval of the medical marijuana company’s API Bulk Manufacturing Registration. What happened: Cannabis...

Attorney Matthew C. Zorn filed a complaint Friday in the U.S. District Court in Washington, D.C. against the Dept of Health and Human Services (HHS) demanding that it produce a requested copy of the letter issuing the cannabis scheduling review directive. What happened...

Republican presidential candidate Vivek Ramaswamy recently gave a domestic policy speech revealing some interesting, if odd, plans concerning the federal government's workforce. Some of the changes he proposed are not quite in line with his previous statements....

Senator Cynthia Lummis (R) and her colleague Senator Steve Daines (R), presented a bill to block cannabis legalization without congressional approval. What happened: On Thursday Lummis introduced the Deferring Executive Authority (DEA) Act, which aims to give Congress...

The American Council of Cannabis Medicine (ACCM) supports the Health and Human Services (HHS) recommendation to reclassify cannabis from a Schedule I to a Schedule III controlled substance. The ACCM said on Thursday that it has begun the DEA rescheduling application for cannabis, a step...

One of the most important results of the potential rescheduling of cannabis to Schedule 3 is eliminating 280e taxes. In previous charts of the week, we have shown that 280e significantly negatively impacts cannabis companies by reducing their internally funded growth and limiting their debt...

The shortage of stimulant-based ADHD (Attention Deficit Hyperactivity Disorder) medications like Adderall, Vyvanse and Ritalin persists, with leading drug makers unable to provide a solution. The shortage began in Fall 2022 and was exacerbated by record-high prescription rates. Teva...

The case around the DEA's decision to terminate the employment of a special agent in 2020 after testing positive for THC is heating up, reported Marijuana Moment’s Kyle Jaeger. Anthony Armour, who served in the agency for 16 years as a special agent, sued the DEA in federal...

Congressman Dave Joyce (R-OH), a co-chair of the Congressional Cannabis Caucus, is refining the so-called Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, a bill that would amend the Controlled Substances Act (CSA) to undo federal criminalization of those acting...

The announcement last week by the department of Health and Human Services (HHS) that it is now recommending the rescheduling of cannabis from schedule I to III, marks a significant inflection point for federal cannabis reform. The timing of the Drug Enforcement Agency (DEA...

In an exclusive interview with Benzinga, Carlos Pinto, chief commercial officer (CCO) of Leafly Holdings Inc. (NASDAQ: LFLY) discussed the strategic shift the cannabis marketplace and education platform has undergone. He also shared his perspective on the Department of Health...

Could the future of healthcare be intertwined with cannabis-based medicines? A recent report by Prohibition Partners, a data, media and tech company operating in the cannabis industry, reveals a remarkable 650% surge in clinical trials using cannabis-based medicines to alleviate symptoms...

“It’s about time,” declared Colorado Gov. Jared Polis in a letter addressed to President Joe Biden several days after the Department of Health and Human Services recommended moving marijuana from a Schedule I to a Schedule III substance. This potentially game-changing...